Myeloproliferative Disorders Drugs Market is Forecasted to Reach a Value of US $11.51 Billion by 2029
Myeloproliferative Disorders Drugs Global Market Report 2025
The Business Research Company's Myeloproliferative Disorders Drugs Global Market Report 2025– Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, November 25, 2025 /EINPresswire.com/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors
What Is The Expected Cagr For The Myeloproliferative Disorders Drugs Market Through 2025?
In the past few years, the market size for drugs used for myeloproliferative disorders has seen consistent growth. Forecasts suggest that it is set to grow from a valuation of $9.47 billion in 2024, to $9.83 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.8%. The driving factors for this growth during the historical period include heightened incidences of myeloproliferative disorders, advancements in the comprehension of disease mechanisms, clinical research and drug development progress, enhancements in diagnosis and screening methodologies, along with increased levels of patient advocacy and awareness.
The market size for drugs treating myeloproliferative disorders is projected to experience consistent expansion in the coming years. It is predicted that by 2029, the market will reach up to $11.51 billion, with a Compound Annual Growth Rate (CAGR) of 4.0%. Factors attributable to this growth for the forecast period include an aging demographic, the rise of precision medicine, the introduction of new therapies, increased attention to rare illnesses worldwide, governmental involvement, and healthcare regulations. The forecast period is also likely to see significant trends such as adopting precision medicine strategies, clinical assessments for exploratory treatments, enhanced symptom control, the extended application of ruxolitinib, and an emphasis on disease biomarkers.
Download a free sample of the myeloproliferative disorders drugs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10681&type=smp
What Are The Driving Factors Impacting The Myeloproliferative Disorders Drugs Market?
The prevalence of myeloproliferative disorders is escalating, and this is forecasted to boost the progress of the market for drugs treating these disorders. Myeloproliferative disorders encompass a vast array of illnesses, differing from acute leukemia in that they entail overgrowth of one or more blood cell lines in the peripheral blood. This surge in myeloproliferative disorders is commonly instigated by genetic irregularities, excessive exposure to radiation, electricity conduits, or substances, and the elderly populace. Medicines for myeloproliferative diseases operate by attaching to the ATP pocket in the active site, obstructing the BCR-ABL protein, thereby restricting the posterior phosphorylation of the targeted protein. This is essential in treating the myeloproliferative disorder. For example, the National Institute of Health, a healthcare research body based in the U.S., reported that chronic myelogenous leukemia was found to be prevalent in men in August 2022. The incidence rate stood at roughly 2.4 new cases per 100,000, compared to 1.4 new cases per 100,000 in women. This was a significant increase from the rate of 1.7 new cases per 100,000 men and women per year recorded in 2020. Consequently, the rising prevalence of myeloproliferative disorders is stimulating the progression of the market for drugs treating these disorders.
Which Players Dominate The Myeloproliferative Disorders Drugs Industry Landscape?
Major players in the Myeloproliferative Disorders Drugs include:
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Incyte Corporation
• Eli Lilly and Co
• F Hoffmann-La Roche Ltd.
• Mylan NV
• Fresenius Kabi AG
What Are The Future Trends Of The Myeloproliferative Disorders Drugs Market?
Product innovation is increasingly becoming a pivotal trend in the myeloproliferative disorder therapeutics market. Big enterprises in the myeloproliferative disorders domain are focusing their endeavors on the development of novel products to cement their market standing. For example, in September 2023, GSK PLC, a company based in the UK and known for its pharmaceutical and biotechnology expertise, disclosed the FDA approval for momelotinib, intended for treating primary myelofibrosis, a form of myeloproliferative disorder (MPD). This groundbreaking drug has a unique modus operandi that has the ability to inhibit three critical signaling pathways: ACVR1 (activin A receptor type I), JAK (Janus kinase) 1, and JAK2. The hindrance of JAK1 and JAK2 may help mitigate splenomegaly and constitutional symptoms. Additionally, the blood-borne hormone hepcidin, whose levels surge in myelofibrosis and induce anemia, are brought down by the direct inhibition of ACVR1.
Global Myeloproliferative Disorders Drugs Market Segmentation By Type, Application, And Region
The myeloproliferative disorders drugs market covered in this report is segmented –
1) By Type: Primary Myelofibrosis, Polycythemia Vera (PV), Essential Thrombocythemia (ET), Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES), Systemic Masto cytosis (SM)
2) By Drug Type: JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Other Drug Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Stores, Drug Stores
Subsegments:
1) By Primary Myelofibrosis: JAK Inhibitors, Immunomodulatory Agents, Supportive Care
2) By Polycythemia Vera (PV): JAK Inhibitors, Hydroxyurea, Phlebotomy, Interferon-alpha
3) By Essential Thrombocythemia (ET): JAK Inhibitors, Hydroxyurea, Anagrelide, Interferon-alpha
4) By Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES): Tyrosine Kinase Inhibitors, Corticosteroids, Interferon-alpha
5) By Systemic Mastocytosis (SM): Tyrosine Kinase Inhibitors, Corticosteroids, Antihistamines, Immunotherapy
View the full myeloproliferative disorders drugs market report:
https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report
Which Region Holds The Largest Market Share In The Myeloproliferative Disorders Drugs Market?
In 2024, North America dominated the market for myeloproliferative disorder drugs. The report predicts the most rapid growth in the Asia-Pacific region during the forecast period. The sectors detailed in the report include North America, Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.
Browse Through More Reports Similar to the Global Myeloproliferative Disorders Drugs Market 2025, By The Business Research Company
Cardiovascular Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Dermatology Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
Gastrointestinal Drug Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
